RxDoctor Payments Data

David Josephson, MD

Neurology · Indianapolis, INNPI 1871597559

Payments from drug & device makers

$18,655in general payments, 2019–2025

Across 1,107 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$2K
  • Amgen$1K
  • Biogen$995
  • Kyowa Kirin, Inc.$775
  • Lilly USA, LLC$768
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$350%
  • Food & beverage$17,63395%
  • Education$9865%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)215$3,339
Novartis164$1,980
Amgen(2 entities)58$1,012
Biogen54$995
Kyowa Kirin, Inc.1$775
Lilly USA, LLC64$768
UCB, Inc.61$734
Sanofi33$683
Supernus Pharmaceuticals, Inc.62$593
EMD Serono, Inc.36$584
Eisai Inc.32$566
MDD US Operations, LLC24$453
Genentech USA, Inc.31$371
Harmony Biosciences LLC15$343
Jazz Pharmaceuticals Inc.11$287
Alnylam Pharmaceuticals Inc.12$281
Bristol Myers Squibb15$272
Livanova USA, Inc.15$271
Johnson & Johnson9$270
Vanda Pharmaceuticals Inc.8$258
AstraZeneca(2 entities)8$244
Argenx US, Inc.9$227
Acorda Therapeutics, Inc12$217
Teva Pharmaceuticals USA, Inc.8$204
Sunovion Pharmaceuticals Inc.16$173
Tanabe Pharma America, Inc.8$162
Catalyst Pharmaceuticals, Inc.6$161
Pfizer9$132
Banner Life Sciences, LLC6$130
Genentech, Inc.1$127
Neurocrine Biosciences, Inc.6$121
Eli Lilly1$103
Cycle Pharmaceuticals Inc4$88
TG Therapeutics, Inc.4$88
Otsuka America Pharmaceutical, Inc.4$85
Lundbeck LLC4$81
SK Life Science, Inc.3$75
Arbor Pharmaceuticals, Inc.4$72
Springworks Therapeutics, Inc.3$70
Amneal Pharmaceuticals LLC4$65
Inspire Medical Systems, Inc.3$65
CSL Behring3$62
Octapharma USA, Inc.2$62
Biohaven Pharmaceuticals, Inc.4$60
Acadia Pharmaceuticals Inc4$57
Almatica Pharma LLC3$54
Avanir Pharmaceuticals, Inc.3$50
Ipsen Biopharmaceuticals, Inc3$49
Sumitomo Pharma America, Inc.3$47
Abbott2$46
Neurelis, Inc.2$45
Takeda Pharmaceuticals U.S.A., Inc.2$45
Axsome Therapeutics, Inc.3$44
Itamar Medical Inc1$43
Sanofi-aventis U.S. LLC2$43
Currax Pharmaceuticals LLC3$41
Assertio Therapeutics, Inc.3$39
Avadel CNS Pharmaceuticals, LLC2$37
Impel Pharmaceuticals Inc.2$35
Biohaven Pharmaceutical Holding Company Ltd.2$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,655 in reported general payments places this provider in the 75th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$145,076
Medicare patients
456
Services billed
3,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin13$133,975
NuplazidPimavanserin Tartrate15$83,785
Nurtec OdtRimegepant Sulfate43$76,044
CopaxoneGlatiramer Acetate13$75,857
Teriflunomide11$68,518
GocovriAmantadine Hcl27$68,510
RytaryCarbidopa/Levodopa14$38,394
BriviactBrivaracetam11$35,033
Aimovig AutoinjectorErenumab-Aooe38$32,912
GlatopaGlatiramer Acetate11$29,568
Topiramate ErTopiramate24$27,359
Emgality PenGalcanezumab-Gnlm23$19,741
Memantine Hcl ErMemantine Hcl136$15,821
Rasagiline Mesylate45$13,360
Carbidopa-LevodopaCarbidopa/Levodopa205$8,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$584$133,97513 claims
Acadia Pharmaceuticals IncNuplazid$57$83,78515 claims
PfizerNurtec Odt$132$76,04443 claims
Teva Pharmaceuticals USA, Inc.Copaxone$204$75,85713 claims
MDD US Operations, LLCGocovri$453$68,51027 claims
Amneal Pharmaceuticals LLCRytary$65$38,39414 claims
UCB, Inc.Briviact$734$35,03311 claims
Lilly USA, LLCCymbalta$768$7,15313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →